Margaret M. Billingsley

TL;DR: Advances in nanoparticle design that overcome heterogeneous barriers to delivery are discussed, arguing that intelligent nanoparticles design can improve efficacy in general delivery applications while enabling tailored designs for precision applications, thereby ultimately improving patient outcome overall.

TL;DR: The ability of ionizable LNPs to deliver mRNA to primary human T cells for functional protein expression is demonstrated and the potential of LNPS to enhance mRNA-based CAR T cell engineering methods is indicated.

TL;DR: The rational design and clinical status of several classes of cancer vaccines are discussed along with novel biomaterial‐based delivery technologies that improve their safety and efficacy.

TL;DR: In this article, an overview of nanomaterials that have been used to overcome clinical barriers to T-cell-based immunotherapies and provide an outlook of this emerging field at the interface of cancer immunotherapy and Nanomaterial design.

TL;DR: This platform, which enables direct barcoding and subsequent quantification of a functional mRNA itself, can accelerate the in vivo screening and design of LNPs for mRNA therapeutic applications such as CRISPR/Cas9 gene editing, mRNA vaccination, and other mRNA-based regenerative medicine and protein replacement therapies.